

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage of Taro-Clobetasol 0.05% Scalp Lotion USP (DIN 02245522) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 24, 2024**. The following grouping was removed from the Critical Supply Product List **June 24, 2024**.

CLOBETASOL 17-PROPIONATE

0.05 % SCALP LOTION

00002216213	MYLAN-CLOBETASOL	MYP	\$ 0.1990
00002245522	TARO-CLOBETASOL	TAR	\$ 0.1990
00001910299	TEVA-CLOBETASOL	TEV	\$ 0.1990
00002213281	DERMOVATE	TPT	\$ 0.8303

Temporary benefits added to the *ADBL*

Due to the unavailability of Jamp-K 8 8 mEq Tablet (NPN 80013005), **Pharmaris K8 8 mEq Sustained-Release Tablet (NPN 80108882)** will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **June 28, 2024**.

As of **June 28, 2024**, all claims for **Pharmaris K8 8 mEq Sustained-Release Tablet (NPN 80108882)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/provider/type/pharmacy/home.php.

Due to the unavailability for pms-Nitrofurantoin 100 mg Capsule (DIN 02455676), **Auro-Nitrofurantoin 100 mg Capsule (DIN 02466392)** will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **July 4, 2024**.

As of **July 4, 2024**, all claims for **Auro-Nitrofurantoin 100 mg Capsule (DIN 02466392)** will be adjudicated to the price published in the most recent *ABCDPL* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/provider/type/pharmacy/home.php.

continued next page

continued from previous page

Removal of temporary benefit from the ADBL

Due to the shortage of Jamp-K Effervescent 975 mg (25 mEq) Tablet (NPN 80033602), **K-Lyte Orange Flavored 25 mEq Effervescent Tablet (DIN 02085992)** manufactured by Wellspring Pharmaceutical Canada Corp. was added as a temporary benefit for the ADBL.

Alberta Blue Cross has confirmed that the shortage for Jamp-K Effervescent 975 mg (25 mEq) Tablet (NPN 80033602) has been resolved.

K-Lyte Orange Flavored 25 mEq Effervescent Tablet (DIN 02085992) will no longer be considered a temporary benefit for the ADBL **after August 12, 2024**. The above grouping was removed from the Critical Supply Product List **July 10, 2024**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

